Cell/Gene Tx channel feed

Gene ther­a­py biotech Lo­can­abio to shut­ter by year’s end

Last year
People
Startups

Cana­di­an gene ther­a­py biotech en­Gene starts trad­ing on Nas­daq af­ter com­plet­ing For­bion SPAC deal

Last year
Financing
Startups

As­traZeneca pays $25M up­front, $80M eq­ui­ty in­vest­ment in­to Cel­lec­tis for gene and cell ther­a­py pact

Last year
Deals

Gen­er­a­tive AI biotech part­ners with can­cer cen­ter in bid to speed up CAR-T de­vel­op­ment in sol­id tu­mors

Last year
Deals
AI

Kite en­lists Epic Bio to ap­ply epi­ge­net­ic edit­ing in cre­at­ing next-gen CAR-T cells

Last year
Deals

Lil­ly makes an­oth­er move for Verve's ge­net­ic med­i­cines, this time buy­ing Beam's opt-in rights

Last year
Deals
Pharma

Sarep­ta's con­fir­ma­to­ry Duchenne tri­al fails to meet end­point, com­pli­cat­ing fu­ture for con­tro­ver­sial drug

Last year
R&D

Lex­eo Ther­a­peu­tics pen­cils in $113M IPO for car­diac and Alzheimer's gene ther­a­py read­outs in 2024

Last year
Financing
Startups

Re­gen­eron gives first glimpse at hear­ing loss gene ther­a­py

Last year
R&D

FDA ques­tions off-tar­get ed­it test­ing on Ver­tex and CRISPR's po­ten­tial sick­le cell gene ther­a­py ahead of ad­comm

Last year
FDA+

Prime Med­i­cine show­cas­es its first in vi­vo edit­ing da­ta in mon­keys and mice

Last year
R&D

Ther­mo Fish­er grows in­to CGT man­u­fac­tur­ing, while Sam­sung Bi­o­log­ics ex­pands in­to AD­Cs

Last year
Manufacturing

Ram­part Bio­science rais­es $125M for non-vi­ral gene ther­a­pies

Last year
Financing
Startups

BioN­Tech CAR-T man­u­fac­tur­ing change leads to fresh da­ta with vac­cine com­bo, with reg­is­tra­tional tri­al plans: #ES­MO23

Last year
R&D
Manufacturing

Up­dat­ed: Verve plans first in-hu­man base edit­ing tri­al in the US af­ter FDA lifts clin­i­cal hold

Last year
R&D

CAR­GO Ther­a­peu­tics heads to Nas­daq in first CAR-T cell ther­a­py IPO pitch of 2023

Last year
Financing
Startups

Up­dat­ed: J&J builds out glob­al man­u­fac­tur­ing ca­pac­i­ty for CAR-T Carvyk­ti

Last year
Manufacturing

Beam cuts 20% of staff, looks to part­ner on base-edit­ed CAR-T one month af­ter dos­ing first pa­tient

Last year
R&D

FDA al­lows first piv­otal tri­al of an in vi­vo gene edit­ing treat­ment from In­tel­lia

Last year
FDA+

Syn­cona eyes buy­out of gene ther­a­py biotech Free­line af­ter ear­ly da­ta in two Gauch­er pa­tients

Last year
Deals

Nkar­ta trims head­count as it sets sights on au­toim­mune cell ther­a­py

Last year
People

Spark lines up next reti­nal gene ther­a­py pact in Barcelona

Last year
Deals
Pharma

eGe­n­e­sis brings kid­ney xeno­trans­plants clos­er to the clin­ic

Last year
R&D

Sana nar­rows fo­cus to ex vi­vo cell ther­a­pies, lays off 29% of staff to reach key clin­i­cal da­ta

Last year
People
R&D
First page Previous page 13141516171819 Next page Last page
A service from the Financial Times